Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 11/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.34 |
| ▸ | DHFR | P00374 | 3/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314454 | 0.91 | NAMPT (0.30) | NAMPT | |
| SCHEMBL29314482 | 0.86 | HIF1A (0.42) | NAMPTDHFRABL1BCR | |
| SCHEMBL29315396 | 0.84 | NAMPT (0.36) | NAMPTDHFR | |
| SCHEMBL29315466 | 0.84 | NAMPT (0.35) | NAMPTDHFR | |
| SCHEMBL29314478 | 0.83 | NAMPT (0.38) | NAMPTDHFR | |
| SCHEMBL29314480 | 0.83 | DHFR (0.35) | NAMPTDHFR | |
| SCHEMBL29314461 | 0.83 | NAMPT (0.36) | NAMPTDHFRABL1BCR | |
| SCHEMBL29325305 | 0.82 | NAMPT (0.42) | NAMPTABL1BCR | |
| SCHEMBL29325284 | 0.82 | NAMPT (0.40) | NAMPTDHFRABL1BCR | |
| SCHEMBL26783757 | 0.80 | PAICS (0.32) | NAMPTTLR9TLR8TLR7ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NAMPT 122/4885TLR9 256/4885TLR8 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.